title: Adjuvant chemotherapy for breast cancer and cognitive impairment.
abstract: Complaints of loss of memory and lack of concentration have been reported by long-term survivors of breast cancer. This mild cognitive impairment (MCI), also called "chemobrain" or "chemofog," has been the subject of a number of studies in the last few years. This cognitive impairment, although usually mild, must be studied to define possible risk factors for its development, and for future research into a preventive or therapeutic treatment approach. Long-term survivors of breast cancer must be followed to detect possible treatment sequelae as soon as possible. Since the number of these long-term survivors has increased in the last years, in part because of more active adjuvant treatments, our knowledge about the long-term side effects of these therapies has also grown.
authors: Medical Oncology Department, Hospital La Paz, Madrid, Spain. alvaro_pinto_marin@hotmail.com
authors: Alvaro Pinto
authors: AP
authors: Marín
authors: Andrés Redondo
authors: AR
authors: Sánchez
authors: Enrique Espinosa
authors: EE
authors: Arranz
authors: Pilar Zamora
authors: PZ
authors: Auñón
authors: Manuel González
authors: MG
authors: Barón
mesh_terms: D001943:Breast Neoplasms / Q000188:drug therapy* / Q000523:psychology; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects*; D003072:Cognition Disorders / Q000139:chemically induced* / Q000175:diagnosis; D003863:Depression / Q000150:complications; D005221:Fatigue / Q000150:complications / Q000209:etiology; D005260:Female; D006801:Humans; D009483:Neuropsychological Tests; D017741:Survivors